177Lu-PSMA radioligand therapy provides a significant response rate with a low toxicity profile. The evidence promotes greater efficacy of radioligand therapy in predominantly lymph node metastatic castration-resistant prostate cancer (mCRPC) and in individuals with chemotherapy-naïve status and lower levels of baseline PSA.